Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zoladex

(Goserelin)

ApprovedSmall molecule

TTerSera Therapeutics LLC

Goserelin is used to treat advanced prostate cancer in men and breast cancer in women by lowering hormone levels. It's also used to help manage endometriosis and uterine fibroids in women.[2] Zoladex is currently approved and in use across 23 indications[4].[1]

Zoladex is one of 501 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

23

Indications

106

Total Trials

29

Active Trials

500

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Metabolic SyndromeActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

AdenomyosisApproved

Salivary Gland CancerApproved

Uterine LeiomyomaActive, not recruiting

Ovarian DysfunctionApproved

LymphomaActive, not recruiting

Hodgkins LymphomaApproved

Uterine FibroidApproved

Ovarian ReserveActive, not recruiting

Metabolic SyndromePhase 2

Active, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

AdenomyosisApproved

Approved

Salivary Gland CancerApproved

Approved

Uterine LeiomyomaApproved

Active, not recruiting

Ovarian DysfunctionApproved

Approved

LymphomaPhase 2

Active, not recruiting

Hodgkins LymphomaApproved

Approved

Uterine FibroidApproved

Approved

Ovarian ReservePreclinical

Active, not recruiting

Showing 10 of 23 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zoladex

TTerSera Therapeutics LLC

Adriamycin

GGynecologic Oncology Group

Spravato

Zinecard

CChildren's Oncology Group

Effexor

WWyeth-Lederle Vaccines

Chantix

PPrism Pharmaceuticals

Zoladex

Luye Pharma Group Ltd.

Beta Blocker

WWeill Medical College of Cornell University

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Prostate Cancer

NCT05003752

Post-ApprovalRecruiting

Stress

NCT06455969

Phase 2Active, not recruiting

Breast Cancer

NCT01723774

Q4 2026

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT05050084

Phase 2Recruiting

Breast Cancer

NCT05594095

Q1 2027

Phase 2Recruiting

Hormone Therapy

NCT05720260

Clinical

Trials by Indication[1]

Breast Cancer43 trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00498901·1 enrolled

Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer

Completed·PPeking Union Medical College Hospital·Phase 3·NCT02483767·98 enrolled

Show 40 more trials

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02586675·7 enrolled

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

Unknown status·—·Phase 2·NCT02072512·180 enrolled

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 2·NCT01989780·160 enrolled

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01240941

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03839823·222 enrolled

PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

Unknown status·—·Phase 2·NCT02917005·160 enrolled

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02115282·608 enrolled

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Unknown status·—··NCT05800197·300 enrolled

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT02278120·672 enrolled

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT03007979·55 enrolled

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT03628066·24 enrolled

Everolimus trIal for Advanced prememopausaL Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02313051·200 enrolled

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01013506

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Terminated·WWashington University School of Medicine·Phase 2·NCT02907918·26 enrolled

Neoadjuvant Goserelin for Triple Negative Breast Cancer

Unknown status·KKasr El Aini Hospital·Phase 2·NCT03444025·180 enrolled

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 3·NCT04478266·1,068 enrolled

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT02333370·88 enrolled

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting·WWashington University School of Medicine·Phase 2·NCT02476786·50 enrolled

Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 3·NCT01530607·416 enrolled

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting·NNational Institute of Oncology, Hungary··NCT05131893·300 enrolled

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed·PPalleos Healthcare GmbH·Phase 2·NCT03272477·257 enrolled

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT03822468·376 enrolled

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Completed· Novartis logo

Novartis·Phase 2·NCT03056755·383 enrolled

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT01723774·84 enrolled

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Recruiting·UUniversity of Chicago·Phase 2·NCT06348134·74 enrolled

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00432172·189 enrolled

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 1·NCT01240928

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01205685·11 enrolled

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Recruiting·YYale University·Phase 2·NCT06953882·140 enrolled

Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

Completed·IInternational Cancer Research Group, United Arab Emirates·Phase 3·NCT03447132·354 enrolled

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Completed·SStanford University·Phase 2·NCT00186121·35 enrolled

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Completed·UUniversity Hospital, Akershus·Phase 2·NCT05163106·85 enrolled

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00429403·1 enrolled

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT03096847·502 enrolled

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT02132390·300 enrolled

Zoladex Plus Tamoxifen in Breast Cancer

Completed·ZZhejiang Cancer Hospital·N/A·NCT00827307·100 enrolled

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Terminated· Novartis logo

Novartis·Phase 2·NCT04862143·2 enrolled

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Active, not recruiting·NNational Cancer Center, Japan·Phase 3·NCT03423199·180 enrolled

Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis.

Completed· Novartis logo

Novartis·Phase 2·NCT03671330·327 enrolled

Prostate Cancer30 trials

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002633·361 enrolled

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00631527·19 enrolled

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Completed· Astellas logo

Astellas·Phase 3·NCT01964170·234 enrolled

Show 27 more trials

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00651326·48 enrolled

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Completed·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT02789878·64 enrolled

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02430480·39 enrolled

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Completed· Ferring logo

Ferring·Phase 3·NCT00884273·182 enrolled

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 3·NCT00388804·39 enrolled

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Completed·UUniversity of Nebraska·Phase 1·NCT00482807·9 enrolled

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

Completed·UUniversity of Washington·Phase 2·NCT00769795·29 enrolled

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Completed· Ferring logo

Ferring·Phase 3·NCT00833248·246 enrolled

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00771017

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

Recruiting·NNational Taiwan University Hospital·N/A·NCT04894188·38 enrolled

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00004635·159 enrolled

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Terminated· Ferring logo

Ferring·Phase 3·NCT00831233·42 enrolled

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Recruiting·MMayo Clinic·Phase 2·NCT06378866·532 enrolled

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT01252693·203 enrolled

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01377389·30 enrolled

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01750398·33 enrolled

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Unknown status·WWonju Severance Christian Hospital·Phase 4·NCT04248621·164 enrolled

Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04356430·75 enrolled

FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer

Unknown status·TTampere University·Phase 4·NCT00293670·573 enrolled

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

Active, not recruiting·GGerman Oncology Center, Cyprus·Phase 1/2·NCT05003752·40 enrolled

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Recruiting·XXijing Hospital·Phase 2·NCT06575257·80 enrolled

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00004124·983 enrolled

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00003653·1,386 enrolled

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Completed· Ferring logo

Ferring·Phase 3·NCT01744366·285 enrolled

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002889·180 enrolled

Tecemotide (L-BLP25) in Prostate Cancer

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT01496131·28 enrolled

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03860987·12 enrolled

Prostate Adenocarcinoma4 trials

Prostate Adenocarcinoma TransCutaneous Hormones

Unknown status·UUniversity College, London·Phase 3·NCT00303784·2,200 enrolled

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Show 1 more trial

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Completed·NNRG Oncology·Preclinical·NCT03070886·612 enrolled

Metastatic Prostate Cancer3 trials

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00028769·41 enrolled

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed· Pfizer logo

Pfizer··NCT05701007·1,083 enrolled

CMAB vs IMAB in Metastatic Prostate Cancer

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT00255268·15 enrolled

Premenopausal2 trials

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309478·1,099 enrolled

Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide

Unknown status·—·Phase 2·NCT03475758·100 enrolled

23 more indications

Breast Neoplasms2 trials

A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer

Active, not recruiting·AAtossa Therapeutics, Inc.·Phase 2·NCT05607004·87 enrolled

preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07287098·600 enrolled

Postmenopausal Women1 trial

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Completed· Novartis logo

Novartis·Phase 3·NCT02941926·3,246 enrolled

Lymphoma1 trial

Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

Enrolling by invitation·—·Phase 2·NCT04536467·80 enrolled

Uterine leiomyoma1 trial

Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

Terminated·UUniversity of Sao Paulo·Phase 4·NCT01738724·14 enrolled

Ovarian Function1 trial

Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women

Unknown status·KKorean Breast Cancer Study Group·Phase 3·NCT00912548·1,234 enrolled

Chemotherapy1 trial

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

Completed·GGBG Forschungs GmbH·Phase 2·NCT00196846·62 enrolled

Atrophy1 trial

Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy

Completed·RRamathibodi Hospital·Phase 4·NCT00851461·10 enrolled

Hormone Therapy1 trial

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT05720260·42 enrolled

Androgen Deprivation Therapy1 trial

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Completed·MMedical College of Wisconsin··NCT02366494·42 enrolled

Menopausal Women1 trial

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

Unknown status·SSamsung Medical Center·Phase 2·NCT01266213·147 enrolled

Metabolic Syndrome1 trial

Testosterone Effects on Men With the Metabolic Syndrome

Withdrawn·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00382057·72 enrolled

Depression1 trial

Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression

Completed·GGitte Moos Knudsen·N/A·NCT02661789·63 enrolled

Ovarian Reserve1 trial

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active, not recruiting·PPeking University People's Hospital··NCT02430103·349 enrolled

Salivary Gland Carcinoma1 trial

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Active, not recruiting·NNational Cancer Center Hospital East·Phase 2·NCT05694819·56 enrolled

Stress1 trial

Adaptions and Resiliency to Multi-Stressor OpeRations

Recruiting·BBradley Nindl·Phase 4·NCT06455969·120 enrolled

Phase II1 trial

Phase II Dutasteride in Combination With CAB vs CAB in SDC

Recruiting·RRadboud University Medical Center·Phase 2·NCT05513365·26 enrolled

Neoadjuvant Therapy1 trial

Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate

Unknown status·WWest China Hospital·Phase 2·NCT04736108·50 enrolled

Adjuvant1 trial

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT02914158·680 enrolled

Endocrine Therapy1 trial

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)

Active, not recruiting·JJules Bordet Institute·Phase 2·NCT04551495·65 enrolled

Early Breast Cancer1 trial

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

Recruiting· Novartis logo

Novartis·Phase 3·NCT05827081·1,400 enrolled

Anatomic Stage I Breast Cancer AJCC v81 trial

Phase 2 Interventional Trial of Ovarian Function Suppression for Breast Cancer (OFS)

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07158021·75 enrolled

Metastatic Breast Cancer1 trial

A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study

Active, not recruiting· Novartis logo

Novartis·Approved·NCT05161195·134 enrolled

Unspecified1 trial

Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting·PProf. Wolfgang Janni·Phase 3·NCT02344472·271 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 29, 1989

ZOLADEX

NDA NDA019726

Jan 11, 1996

ZOLADEX

NDA NDA020578

Sources

References

[1]
ClinicalTrials.gov — 106 trial records for Goserelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Zoladex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Goserelin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Goserelin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020578). U.S. Food & Drug Administration.
[6]
SEC EDGAR — TerSera Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Gonadotropin-Releasing Hormone Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: TTerSera Therapeutics LLC

Related News